{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:05:52Z","timestamp":1783667152730,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.critrevonc.2024.104529","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T04:39:10Z","timestamp":1728016750000},"page":"104529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Outcomes in randomized controlled trials of therapeutic interventions for multiple myeloma: A systematic review"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5775-2241","authenticated-orcid":false,"given":"Maria","family":"Mainou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Tsapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Michailidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Malandris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Avgerinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris","family":"Liakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Tsapas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104529_bib1","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal residual disease in Myeloma: application for clinical care and new drug registration","volume":"27","author":"Anderson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104529_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma","volume":"22","author":"Anderson","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2024.104529_bib3","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.281322","article-title":"Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma","author":"Asher","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104529_bib4","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2024.104529_bib5","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2021-149564","article-title":"Enhancing diversity in oncology clinical trials: findings of a case study in improving black patient representation in a multiple myeloma trial","volume":"138","author":"Bhandari","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104529_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2991\/chi.d.191101.001","article-title":"Moving toward continuous therapy in multiple myeloma","volume":"1","author":"Bonello","year":"2019","journal-title":"Clin. Hematol. Int"},{"key":"10.1016\/j.critrevonc.2024.104529_bib7","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1470-2045(23)00319-4","article-title":"Common Sense Oncology: outcomes that matter","volume":"24","author":"Booth","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","article-title":"Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.critrevonc.2024.104529_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41571-022-00665-7","article-title":"Overall survival as a primary end point in multiple myeloma trials","volume":"19","author":"Cliff","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib10","unstructured":"Combined FDA and Applicants ODAC Briefing Document, 2024. Oncologic Drugs Advisory Committee Meeting. Use of Minimal Residual Disease (MRD) as an Endpoint in Multiple Myeloma Clinical Trials [WWW Document]. URL \u3008https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/april-12-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04122024\u3009 (accessed 9.28.24)."},{"key":"10.1016\/j.critrevonc.2024.104529_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267979","article-title":"Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma","volume":"17","author":"Daniele","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2024.104529_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.yao.2022.02.012","article-title":"Moving toward a cure in multiple myeloma: eradication of measurable residual disease","volume":"2","author":"Derman","year":"2022","journal-title":"Adv. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bjh.18568","article-title":"Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis","volume":"200","author":"Etekal","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib14","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), 2023. Guideline on the clinical evaluation of anticancer medicinal products [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/evaluation-anticancer-medicinal-products-man-scientific-guideline\u3009 (accessed 9.28.24)."},{"key":"10.1016\/j.critrevonc.2024.104529_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2023.100433","article-title":"Under-representation of black patients with multiple myeloma in studies supporting International myeloma working group guidelines","volume":"37","author":"Fahmawi","year":"2023","journal-title":"J. Cancer Policy"},{"key":"10.1016\/j.critrevonc.2024.104529_bib16","unstructured":"FDA Briefing Document, 2024. Oncologic Drugs Advisory Committee Meeting. BLA 125746\/Supplement 74 [WWW Document]. URL \u3008https:\/\/www.fda.gov\/media\/176986\/download\u3009 (accessed 9.28.24)."},{"key":"10.1016\/j.critrevonc.2024.104529_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1470-2045(22)00015-8","article-title":"Progression-free survival: it is time for a new name","volume":"23","author":"Gyawali","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2017.72","article-title":"Combining drugs and extending treatment-a PFS end point is not sufficient","author":"Gyawali","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0363","article-title":"Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2024.104529_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","author":"Haslam","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104529_bib21","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-019-0495-9","article-title":"Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?","author":"Holstein","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.critrevonc.2024.104529_bib22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.mayocp.2016.02.012","article-title":"Strength of validation for surrogate end points used in the us food and drug administration\u2019s approval of oncology drugs","volume":"91","author":"Kim","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.critrevonc.2024.104529_bib23","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(19)31711-8","article-title":"Surrogate endpoints in randomised controlled trials: a reality check","volume":"394","author":"Kumar","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104529_bib25","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2024.104529_bib26","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104529_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1600-0609.2009.01303.x","article-title":"Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations","volume":"83","author":"Kvam","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"Kyle","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib29","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104529_bib30","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.3390\/cancers15245764","article-title":"Guidelines for the use and reporting of patient-reported outcomes in multiple myeloma clinical trials","volume":"15","author":"Laane","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2024.104529_bib31","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1158\/1078-0432.CCR-16-0866","article-title":"New developments in diagnosis, prognosis, and assessment of response in multiple myeloma","volume":"22","author":"Landgren","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104529_bib32","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s11136-019-02392-6","article-title":"How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? a systematic review","volume":"29","author":"LeBlanc","year":"2020","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.critrevonc.2024.104529_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101910","article-title":"SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of \u2018biomarker-defined early multiple myeloma\u2019\u2014a systematic review with meta-analysis","volume":"58","author":"Ludwig","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2024.104529_bib34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/asheducation-2017.1.212","article-title":"Fixed duration vs continuous therapy in multiple myeloma","volume":"2017","author":"Ludwig","year":"2017","journal-title":"Hematol.: Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.critrevonc.2024.104529_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/ejh.12868","article-title":"Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis","volume":"98","author":"Mainou","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib36","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S0140-6736(21)00274-9","article-title":"Multiple myeloma triplet therapies: baseline characteristics and control groups","volume":"397","author":"Mohyuddin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104529_bib37","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/S2352-3026(22)00264-2","article-title":"A survey on the patient perspective on cure in multiple myeloma","volume":"9","author":"Mohyuddin","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib38","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ajh.26166","article-title":"Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: a systematic review","volume":"96","author":"Mohyuddin","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib39","first-page":"998","article-title":"Multiple myeloma guidelines and their recent updates: implications for imaging. rofo fortschritte auf dem gebiet der rontgenstrahlen","volume":"191","author":"Mosebach","year":"2019","journal-title":"und der Bildgeb. Verfahr."},{"key":"10.1016\/j.critrevonc.2024.104529_bib40","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2024.104529_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15759","article-title":"Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma","volume":"185","author":"Nielsen","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","article-title":"A systematic review of health-related quality of life in longitudinal studies of myeloma patients","volume":"99","author":"Nielsen","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12012","article-title":"What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools","volume":"89","author":"Osborne","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib44","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib45","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib46","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104529_bib47","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: a clash of philosophies","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104529_bib48","doi-asserted-by":"crossref","first-page":"A537","DOI":"10.1016\/j.jval.2014.08.1720","article-title":"A systematic literature review of the humanistic burden of multiple myeloma","volume":"17","author":"Rizzo","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2024.104529_bib49","unstructured":"RStudio Team (2020). RStudio: Integrated Development for R. RStudio, PBC, Boston, MA URL \u3008http:\/\/www.rstudio.com\/\u3009., n.d."},{"key":"10.1016\/j.critrevonc.2024.104529_bib50","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","article-title":"Review of health-related quality of life data in multiple myeloma patients treated with novel agents","volume":"27","author":"Sonneveld","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2024.104529_bib51","article-title":"Race\/ethnicity reporting and representation in US clinical trials: a cohort study","volume":"11","author":"Turner","year":"2022","journal-title":"Lancet Reg. Health - Am."},{"key":"10.1016\/j.critrevonc.2024.104529_bib52","unstructured":"U.S. department of health and human services, Food and Drug Administration, Oncology Center of Excellence, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 2018. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Guidance for Industry [WWW Document]. URL \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics\u3009 (accessed 9.28.24)."},{"key":"10.1016\/j.critrevonc.2024.104529_bib53","unstructured":"U.S. department of health and human services, Food and Drug Administration, Oncology Center of Excellence (OCE), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 2021. Core Patient-Reported Outcomes in Cancer Clinical Trials. Guidance for Industry. Draft guidance [WWW Document]. URL \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials\u3009 (accessed 9.28.24)."},{"key":"10.1016\/j.critrevonc.2024.104529_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00750-1","article-title":"Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015\u20132020","volume":"12","author":"Van Oekelen","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2024.104529_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1231720","article-title":"Multiple myeloma: challenges with deciding the optimal sequencing strategy","author":"Walia","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2024.104529_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102821","article-title":"Evaluation of spin in oncology clinical trials","author":"Wayant","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T04:04:54Z","timestamp":1732939494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824002725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":56,"alternative-id":["S1040842824002725"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104529","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes in randomized controlled trials of therapeutic interventions for multiple myeloma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104529"}}